The acquisition will spearhead Navitas’ clinical business by using DataCeutics’ capabilities with Navitas’ AI-driven clinical platform, it said.
“We are delighted to begin 2019 on a high note with this key acquisition. DataCeutics strengthens our capabilities in Data Sciences and FSP/BPO services and widens our therapeutic expertise in cardiology, oncology, pulmonology, CNS, infectious diseases, etc. The addition of these competencies translates to business expansion in North American, European and Asian markets,” Dr. Krishnan Rajagopalan, chief growth officer, Navitas Life Sciences, said.
“We are looking forward to bolstering the clinical business further translating to a healthier pipeline in the coming quarters,” he said.
Financial terms of the deal were not disclosed.